| Ytd | 87.95% | |
| 1y | 348.86% |
| Open | 10.15 | Prev Close | 10.31 | Low | 9.60 | High | 10.29 | Mkt Cap | 699.80M |
| Vol | 1.82M | Avg Vol | 1.36M | EPS | -0.92 | P/E | N/A | Forward P/E | -3.96 |
| Beta | 0.10 | Short Ratio | 2.94 | Inst. Own | 17.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.24 | 200-d Avg | 6.61 | 1yr Est | 7.00 |
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyl
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Chec
B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a